Effects (MACE and bleeding events) of ticagrelor combined with omeprazole on patients with acute myocardial infarction undergoing primary PCI
Background: This study aimed to investigate the effect of ticagrelor combined with omeprazole on patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI). Methods: Eighty-six patients with AMI who underwent primary PCI in Xinxiang Central Hospital b...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-09-01
|
| Series: | Hellenic Journal of Cardiology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1109966618305001 |
| _version_ | 1819143729832787968 |
|---|---|
| author | Fucheng Zhang Shuhong Su Yuyan Hou Lipei Zhao Zhifang Wang Fen Liu Fengli Wu Li Zhang |
| author_facet | Fucheng Zhang Shuhong Su Yuyan Hou Lipei Zhao Zhifang Wang Fen Liu Fengli Wu Li Zhang |
| author_sort | Fucheng Zhang |
| collection | DOAJ |
| description | Background: This study aimed to investigate the effect of ticagrelor combined with omeprazole on patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI). Methods: Eighty-six patients with AMI who underwent primary PCI in Xinxiang Central Hospital between July 2015 and December 2016 were included and divided randomly into the observation group and the control group by the draw, with 43 patients in each group. All patients were routinely treated with dual antiplatelet therapy with aspirin plus ticagrelor. Omeprazole was used in the observation group and placebo was used in the control group. Data of baseline patient characteristics, platelet response index (PRI), ADP-induced platelet aggregation (ADP-Ag), major adverse cardiac events (MACE), and incidence of bleeding events were recorded and compared between both groups. Results: PRI and ADP-Ag at 7 days, 1 month, and 6 months after operation in both groups were significantly lower than those in the same group before administration (p < 0.017). Incidence of bleeding events in the observation group was significantly lower than that in the control group (p < 0.05). Conclusion: For patients with AMI undergoing primary PCI, omeprazole was found to reduce the incidence of gastrointestinal bleeding without reducing the antiplatelet aggregation effect of ticagrelor or increasing the risk of MACE, which is worthy of clinical promotion. |
| first_indexed | 2024-12-22T12:30:52Z |
| format | Article |
| id | doaj.art-76f22c110a104358b810e9a4d88053b8 |
| institution | Directory Open Access Journal |
| issn | 1109-9666 |
| language | English |
| last_indexed | 2024-12-22T12:30:52Z |
| publishDate | 2020-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hellenic Journal of Cardiology |
| spelling | doaj.art-76f22c110a104358b810e9a4d88053b82022-12-21T18:25:40ZengElsevierHellenic Journal of Cardiology1109-96662020-09-01615306310Effects (MACE and bleeding events) of ticagrelor combined with omeprazole on patients with acute myocardial infarction undergoing primary PCIFucheng Zhang0Shuhong Su1Yuyan Hou2Lipei Zhao3Zhifang Wang4Fen Liu5Fengli Wu6Li Zhang7Department of Cardiology, Xinxiang Central Hospital, Xinxiang, Henan 45300 ChinaDepartment of Cardiology, Xinxiang Central Hospital, Xinxiang, Henan 45300 ChinaDepartment of Cardiology, Xinxiang Central Hospital, Xinxiang, Henan 45300 ChinaDepartment of Cardiology, Xinxiang Central Hospital, Xinxiang, Henan 45300 ChinaDepartment of Cardiology, Xinxiang Central Hospital, Xinxiang, Henan 45300 China; Corresponding author. Department of Cardiology, Xinxiang Central Hospital, 53 Jinsui Road, Xinxiang, Henan 45300. China.Department of Hepatology, 371 PLA Hospital, Xinxiang, Henan 45300 ChinaDepartment of Gastroenterology, Xinxiang, Henan 45300 ChinaDepartment of Gastroenterology, Xinxiang, Henan 45300 ChinaBackground: This study aimed to investigate the effect of ticagrelor combined with omeprazole on patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI). Methods: Eighty-six patients with AMI who underwent primary PCI in Xinxiang Central Hospital between July 2015 and December 2016 were included and divided randomly into the observation group and the control group by the draw, with 43 patients in each group. All patients were routinely treated with dual antiplatelet therapy with aspirin plus ticagrelor. Omeprazole was used in the observation group and placebo was used in the control group. Data of baseline patient characteristics, platelet response index (PRI), ADP-induced platelet aggregation (ADP-Ag), major adverse cardiac events (MACE), and incidence of bleeding events were recorded and compared between both groups. Results: PRI and ADP-Ag at 7 days, 1 month, and 6 months after operation in both groups were significantly lower than those in the same group before administration (p < 0.017). Incidence of bleeding events in the observation group was significantly lower than that in the control group (p < 0.05). Conclusion: For patients with AMI undergoing primary PCI, omeprazole was found to reduce the incidence of gastrointestinal bleeding without reducing the antiplatelet aggregation effect of ticagrelor or increasing the risk of MACE, which is worthy of clinical promotion.http://www.sciencedirect.com/science/article/pii/S1109966618305001ticagreloromeprazolemajor adverse cardiac eventsbleeding eventsacute myocardial infarction |
| spellingShingle | Fucheng Zhang Shuhong Su Yuyan Hou Lipei Zhao Zhifang Wang Fen Liu Fengli Wu Li Zhang Effects (MACE and bleeding events) of ticagrelor combined with omeprazole on patients with acute myocardial infarction undergoing primary PCI Hellenic Journal of Cardiology ticagrelor omeprazole major adverse cardiac events bleeding events acute myocardial infarction |
| title | Effects (MACE and bleeding events) of ticagrelor combined with omeprazole on patients with acute myocardial infarction undergoing primary PCI |
| title_full | Effects (MACE and bleeding events) of ticagrelor combined with omeprazole on patients with acute myocardial infarction undergoing primary PCI |
| title_fullStr | Effects (MACE and bleeding events) of ticagrelor combined with omeprazole on patients with acute myocardial infarction undergoing primary PCI |
| title_full_unstemmed | Effects (MACE and bleeding events) of ticagrelor combined with omeprazole on patients with acute myocardial infarction undergoing primary PCI |
| title_short | Effects (MACE and bleeding events) of ticagrelor combined with omeprazole on patients with acute myocardial infarction undergoing primary PCI |
| title_sort | effects mace and bleeding events of ticagrelor combined with omeprazole on patients with acute myocardial infarction undergoing primary pci |
| topic | ticagrelor omeprazole major adverse cardiac events bleeding events acute myocardial infarction |
| url | http://www.sciencedirect.com/science/article/pii/S1109966618305001 |
| work_keys_str_mv | AT fuchengzhang effectsmaceandbleedingeventsofticagrelorcombinedwithomeprazoleonpatientswithacutemyocardialinfarctionundergoingprimarypci AT shuhongsu effectsmaceandbleedingeventsofticagrelorcombinedwithomeprazoleonpatientswithacutemyocardialinfarctionundergoingprimarypci AT yuyanhou effectsmaceandbleedingeventsofticagrelorcombinedwithomeprazoleonpatientswithacutemyocardialinfarctionundergoingprimarypci AT lipeizhao effectsmaceandbleedingeventsofticagrelorcombinedwithomeprazoleonpatientswithacutemyocardialinfarctionundergoingprimarypci AT zhifangwang effectsmaceandbleedingeventsofticagrelorcombinedwithomeprazoleonpatientswithacutemyocardialinfarctionundergoingprimarypci AT fenliu effectsmaceandbleedingeventsofticagrelorcombinedwithomeprazoleonpatientswithacutemyocardialinfarctionundergoingprimarypci AT fengliwu effectsmaceandbleedingeventsofticagrelorcombinedwithomeprazoleonpatientswithacutemyocardialinfarctionundergoingprimarypci AT lizhang effectsmaceandbleedingeventsofticagrelorcombinedwithomeprazoleonpatientswithacutemyocardialinfarctionundergoingprimarypci |